Despite a European expert consensus statement on the systemic treatment of alopecia areata, the absence of global guidelines and limited information on the long-term safety of JAKi use still poses challenges to clinicians. A cross-sectional survey was conducted to assess the use of JAKi in AA among consultant dermatologists in Ireland.
Grechin et al. (Sat,) studied this question.